Mesoblast Ltd ADR (MESO)

$17.30 +0.63 (3.78%)
Market Cap 1.91B
Revenue (ttm) 5.90M
Net Income (ttm) -87.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,490.85%
Debt to Equity Ratio 0.24
Volume 535,000
Avg Vol 483,916
Day's Range N/A - N/A
Shares Out 114.68M
Stochastic %K 22%
Beta 3.36
Analysts Strong Sell
Price Target $22.50

Latest News on MESO

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Jan 10, 2025, 10:31 AM EST - 7 days ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

SANA

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Dec 19, 2024, 6:38 AM EST - 4 weeks ago

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

Dec 18, 2024, 7:08 PM EST - 4 weeks ago

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Dec 18, 2024, 4:58 PM EST - 4 weeks ago

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Mesoblast to be Added to Nasdaq Biotechnology Index

Dec 18, 2024, 7:30 AM EST - 4 weeks ago

Mesoblast to be Added to Nasdaq Biotechnology Index

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Dec 12, 2024, 12:08 PM EST - 5 weeks ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

CAPR XBI

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Dec 4, 2024, 6:32 PM EST - 6 weeks ago

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Dec 2, 2024, 6:20 PM EST - 6 weeks ago

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Oct 30, 2024, 7:11 PM EDT - 2 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30, 2024, 4:24 PM EDT - 3 months ago

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Sep 29, 2024, 8:55 PM EDT - 3 months ago

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Aug 28, 2024, 9:04 PM EDT - 5 months ago

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Aug 28, 2024, 7:27 PM EDT - 5 months ago

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Mesoblast Financial Results and Corporate Update Webcast

Aug 27, 2024, 7:25 PM EDT - 5 months ago

Mesoblast Financial Results and Corporate Update Webcast

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

Jul 30, 2024, 9:13 PM EDT - 6 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jul 23, 2024, 7:53 AM EDT - 6 months ago

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Jul 21, 2024, 8:45 PM EDT - 6 months ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jul 8, 2024, 8:37 PM EDT - 6 months ago

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Jul 1, 2024, 1:55 AM EDT - 7 months ago

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Mesoblast Corporate Presentation at Investor Conference

Jun 2, 2024, 8:23 PM EDT - 8 months ago

Mesoblast Corporate Presentation at Investor Conference

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

Apr 29, 2024, 9:05 PM EDT - 9 months ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mar 25, 2024, 10:34 PM EDT - 10 months ago

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

Mar 13, 2024, 7:30 PM EDT - 11 months ago

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Mar 10, 2024, 7:54 PM EDT - 11 months ago

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript

Feb 29, 2024, 6:07 PM EST - 11 months ago

Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Feb 28, 2024, 5:57 PM EST - 11 months ago

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Feb 14, 2024, 7:46 PM EST - 1 year ago

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Jan 30, 2024, 9:13 PM EST - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Top 4 Health Care Stocks That May Explode This Month - Mesoblast (NASDAQ:MESO), Humana (NYSE:HUM)

Jan 26, 2024, 7:03 AM EST - 1 year ago

Top 4 Health Care Stocks That May Explode This Month - Mesoblast (NASDAQ:MESO), Humana (NYSE:HUM)

HUM MPLN NEOG

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Jan 18, 2024, 6:36 PM EST - 1 year ago

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Mesoblast Has Major Hurdles

Dec 22, 2023, 6:37 PM EST - 1 year ago

Mesoblast Has Major Hurdles

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Nov 26, 2023, 6:56 PM EST - 1 year ago

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD

Nov 21, 2023, 6:32 PM EST - 1 year ago

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023

Oct 30, 2023, 8:04 PM EDT - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Sep 26, 2023, 6:18 AM EDT - 1 year ago

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval

Sep 21, 2023, 3:30 AM EDT - 1 year ago

Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval

Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript

Aug 30, 2023, 10:25 PM EDT - 1 year ago

Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

Aug 30, 2023, 7:07 PM EDT - 1 year ago

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

FDA rejects Mesoblast's cell therapy for bone marrow transplant complications

Aug 3, 2023, 10:01 PM EDT - 1 year ago

FDA rejects Mesoblast's cell therapy for bone marrow transplant complications

Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Aug 3, 2023, 8:10 PM EDT - 1 year ago

Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023

Jul 30, 2023, 8:31 PM EDT - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023

Mesoblast: PDUFA In Less Than 2 Weeks

Jul 25, 2023, 10:00 AM EDT - 1 year ago

Mesoblast: PDUFA In Less Than 2 Weeks

Mesoblast Director Philip R. Krause, M.D.

Jun 4, 2023, 8:21 PM EDT - 1 year ago

Mesoblast Director Philip R. Krause, M.D.

Mesoblast Limited (MESO) Q3 2023 Earnings Call Transcript

May 25, 2023, 11:38 PM EDT - 1 year ago

Mesoblast Limited (MESO) Q3 2023 Earnings Call Transcript

Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023

May 25, 2023, 7:28 PM EDT - 1 year ago

Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023

Appendix 4C Quarterly Activity Report

Apr 27, 2023, 9:00 PM EDT - 1 year ago

Appendix 4C Quarterly Activity Report

Mesoblast Completes Private Placement

Apr 25, 2023, 8:47 PM EDT - 1 year ago

Mesoblast Completes Private Placement

FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing

Mar 21, 2023, 9:20 PM EDT - 1 year ago

FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing

FDA Accepts Mesoblast's Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023

Mar 7, 2023, 7:03 PM EST - 2 years ago

FDA Accepts Mesoblast's Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023